9 completed, 1 terminated, 1 unknown. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow lestaurtinib: new trials by email Literature Review of lestaurtinib trials Research Report on lestaurtinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
| Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Asparaginase, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia | Phase 3 | Completed | Children's Oncology Group | 218 | 2008-01-15 | 2024-07-15 |
| Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis lestaurtinib - Polycythemia Vera, Essential Thrombocytosis | Phase 2 | Completed | Cephalon | 39 | 2007-12-01 | 2015-10-08 |
| CEP-701 for PH-negative Myelofibrosis CEP-701 - Leukemia, Myelofibrosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 27 | 2007-06-01 | 2012-06-25 |
| Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia cytarabine, idarubicin, lestaurtinib - Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 14 | 2007-06-01 | 2017-03-15 |
| Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma Oral CEP-701 - Myeloma | Phase 2 | Terminated | Cephalon | 2006-04-01 | 2012-08-23 | |
| Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis CEP-701 20mg, CEP-701 40mg, CEP-701 60mg - Psoriasis | Phase 2 | Completed | Cephalon | 46 | 2005-06-01 | 2012-08-23 |
| Study of CEP-701 in Treatment of Prostate Cancer CEP-701 - Prostate Cancer | Phase 2 | Completed | Cephalon | 30 | 2004-03-01 | 2012-08-24 |
| Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) CEP-701, high-dose cytarabine, Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy) - Acute Myeloid Leukemia | Phase 2 | Completed | Cephalon | 224 | 2003-10-01 | 2016-07-21 |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma lestaurtinib - Neuroblastoma | Phase 1 | Completed | New Approaches to Neuroblastoma Therapy Consortium | 47 | 2003-08-01 | 2023-04-10 |
| Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation CEP-701 60mg, Cep-701 80mg, Cep-701 40mg - Leukemia, Myeloid | Phase 2 | Completed | Cephalon | 37 | 2002-01-01 | 2012-08-23 |
Leukemia (2) · Leukemia, Myeloid, Acute (2) · Polycythemia Vera (2) · Primary Myelofibrosis (2) · Thrombocythemia, Essential (2) · Congenital Abnormalities (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid (1) · Neoplasms, Plasma Cell (1) · Neuroblastoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1) · Psoriasis (1)
Cephalon (6) · Children's Oncology Group (2) · M.D. Anderson Cancer Center (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · Ronald Hoffman (1)
United States (10) · Canada (3) · Australia (2) · New Zealand (2) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1)
Donald Small, MD, PhD (1) · Garrett M. Brodeur, MD (1) · Joanne M Hilden (1) · John M. Maris, MD (1) · Patrick A. Brown, MD (1) · Peter Brown (1) · Ronald Hoffman, MD (1) · Srdan Verstovsek, M.D. (1)
PMID 20008298, PMID 21270442, PMID 24903629, PMID 25563429, PMID 32414848
P01CA081403 (1), P01CA108671 (1), U10CA098543 (1), U10CA180886 (1)